PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Physostigmine→

Physostigmine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
57-47-6
Molecular formula
C15H21N3O2
Molecular weight
275.35 g/mol
Drug class
Reversible carbamate acetylcholinesterase inhibitorcentrally acting cholinergic agent
Mechanism of action
Reversibly inhibits acetylcholinesterase, increasing acetylcholine concentrations at central and peripheral cholinergic synapses. This can overcome muscarinic receptor blockade in anticholinergic toxicity.
Indications / reported uses
  • Reversal of clinically significant central anticholinergic toxicity, particularly delirium, in carefully selected patients under specialist toxicology guidance.
  • Ophthalmic use for selected glaucoma indications is historical or jurisdiction- and formulation-specific.

Sources: https://www.ontariopoisoncentre.ca/siteassets/pdfs/english/patient-care-resources-documents/physostigminesalicylate_20260506.pdf · https://www.ncbi.nlm.nih.gov/mesh/68010827/

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Physostigmine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Physostigmine Permitted Daily Exposure (PDE) report (the Physostigmine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Physostigmine Occupational Exposure Limit (OEL) report (the Physostigmine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.